'Locked' cancer therapeutic activates in tumors, limiting off-target exposure in mice
Although there are many cancer treatments available today that effectively eliminate abnormal cells, these therapies may also damage healthy cells, leading to unwanted side effects.
Researchers have developed a novel cancer therapeutic called Pro-LYTAC, designed to be activated only within tumor cells. This innovative treatment holds promise for reducing off-target exposure in patients. Traditional chemotherapy, which affects all rapidly dividing cells, often damages healthy tissues, leading to severe side effects.
In contrast, the Pro-LYTAC approach employs a clever strategy: keeping the treatment compound inactive until it reaches the tumor microenvironment. The compound, known as Pro-LYTAC, is activated by glutathione—a substance present in higher concentrations within tumors. Once activated, Pro-LYTAC targets and degrades a protein used by cancer cells to evade the immune system.
This degradation exposes the tumor cells to the body's immune response, making them more susceptible to attack. In laboratory tests involving mice with triple-negative breast cancer, Pro-LYTAC demonstrated superior tumor reduction compared to a control group receiving saline solution. Importantly, the treatment was found to remain concentrated in the tumors themselves, with minimal presence in the liver.
This suggests that the locked therapeutic prevented liver damage, indicating potential for reduced side effects. While still in the early stages, Pro-LYTAC represents a promising avenue for safer, more targeted cancer therapies.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.
